Brainsway to test device against cocaine addition
The FDA has granted investigational device exemptions for the company's Deep TMS device for this indication.
The trial, which will include 30 patients, will be financed by the National Institute on Drug Abuse (NIDA), a unit of the National Institutes of Health (NIH). If and when the Deep TMS is commercialized for the treatment of cocaine addition, Brainsway will pay royalties to NIDA.
The Deep TMS (Transcranial Magnetic Stimluation) is a non-invasive treatment of brain disorders by activating or suppressing neuron activity in the brain to treat psychiatric or neurological disorders.
Brainsway, run by CEO Uzi Sofer, has initiated procedures to list on Nasdaq in the fourth quarter of 2010.
Brainsway's share price rose 0.6% by mid-afternoon, giving a market cap of NIS 344 million.
Published by Globes [online], Israel business news - www.globes-online.com - on August 22, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010
- Tel Aviv market report
- Tel Aviv Stock Exchange
- Israeli stocks in NY
- Arbitrage gaps for dual-listed stocks
- Israeli stocks in Europe
- Israeli stocks on other markets
- Tel Aviv 25 options
- Mutual funds
- Current representative shekel rates
- Historical representative shekel rates
- Bank shekel rates
- Shekel/dollar options